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OBJECTIVES: To evaluate usage and persistency of atypical
anti-psychotics among schizophrenia patients utilizing a
managed care database. METHODS: A retrospective study
utilizing the Pharmetrics claims database was conducted. All
patients with a diagnosis of schizophrenia (ICD 9 codes 295.0 to
295.9) in 2003 were included in the analysis. Patients were
required to have a minimum 12 months of continuous eligibility
following their index diagnosis. A subset of patients was classi-
ﬁed on the basis of ﬁrst atypical anti-psychotic mono-therapy
treatment (Risperidone, Olanzapine, Quetiapine, Aripiprazole or
Ziprasdone). Persistency (%) in this group was calculated by
following a closed cohort of patients on a speciﬁc atypical anti-
psychotic therapy from month one to month 12. Patients who
dropped-off therapy and then re-initiated the same atypical agent
within the 12 month period (re-starts) were included in the
analysis. RESULTS: A total of 6418 patients were analyzed. Of
these 60.4% were currently on an antipsychotic (typical/ atypi-
cal) treatment. Atypical mono-therapy including clozapine was
used by 51.7%, combination atypical therapy by 30.5%; the
remaining 17.8% of the currently treated cohort were on typical
anti-psychotics. The subset of 1777 patients on atypical mono-
therapy consisted of 668 (37.6%) Risperidone; 754 (42.4%)
Olanzapine; 228 (12.8%) Quetiapine; 105 (5.9%) Ziprasidone.
Aripiprazole patients (n = 24) were excluded from this analysis.
Olanzapine and Risperidone patients were more persistent (60%
and 59%) compared to Quetiapine (44%) and Ziprasidone
(40%). CONCLUSION: Majority of schizophrenia patients are
currently treated with atypical anti-psychotics with Olanzapine
and Risperidone in the lead in terms of treatment share and
persistency.
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OBJECTIVES: The purpose of this study was to quantify the
extent of nonadherence across antidepressants and to determine
the rate of switching within the class. METHODS: Blinded pre-
scription data from two national retail pharmacy chains was
analyzed for 417,002 patients taking sertraline, venlafaxine, par-
oxetine, and escitalopram. Cumulative drug consumption (total
days supply) during the one year follow up period was employed
as the measure of adherence. Kaplan Meier estimates of survival
(persistence) curves were used to assess the time to discontinua-
tion and to calculate the one year rate of discontinuation. Base-
line patient characteristics, including age, gender, geographic
region, median income, index quantity dispensed, population
density, co-pay, and index reﬁll and days supply prescribed were
analyzed. RESULTS: Adherence data across these antidepres-
sants showed that escitalopram patients obtained the fewest days
of medication (161.26), and venlafaxine patients had the greatest
number of days of therapy (191.54). At day 60, 30% of ven-
lafaxine patients, 34% of sertraline patients, and 40% of parox-
etine and escitalopram patients discontinued therapy. After 6
months, 60% of venlafaxine patients, 64% of sertraline patients,
68% of paroxetine patients, and 70% of escitalopram patients
discontinued therapy. The rate of switching to another agent was
3.67% for paroxetine, 3.14% for venlafaxine, 2.95% for escit-
alopram, and 2.1% for sertraline. CONCLUSION: Even though
antidepressant medications are effective in controlling depres-
sion, their effectiveness is reduced by the lack of adherence to
therapy. Adherence can vary signiﬁcantly across the agents
within a class. Efforts to maintain patients on antidepressant
therapy at the initiation of treatment are needed and most likely
will affect future adherence.
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OBJECTIVES: This study assesses the validity and responsive-
ness over changes of the English version of the S-QoL, ﬁrst
schizophrenia-speciﬁc health-related quality of life scale devel-
oped from patients’ viewpoint on the need-based framework.
METHODS: The S-QoL, comprising 41 items exploring eight
dimensions (Psychological Well-being, Self-esteem, Relations
with Family, Relations with Friends, Resilience, Physical Well-
being, Autonomy and Sentimental Life), was ﬁrst developed and
validated in French. After a standard backward-forward trans-
lation process, its English version was tested in a sample of
patients with schizophrenia. Two assessments were performed:
baseline and 12 weeks later. Psychometric properties (validity
and sensitivity over changes) were evaluated using methods from
Classical Test Theory, Rasch analyses and structural equation
modelling. RESULTS: A total of 128 patients ﬁlled-in the S-QoL.
The factorial structure of the original version was globally
retrieved. The questionnaire was well accepted (missing dimen-
sion rates lower than 3%). Cronbach’s alphas were greater than
0.70 for 6 of the 8 dimensions. The S-QoL dimensions and total
score were statistically correlated with depression assessed with
the Calgary Depression Scale for Schizophrenia (CDSS), and
severity of symptoms measured by the Positive and Negative
Symptoms Scale (PANSS). Using the sub-sample of patients rated
“Very much Improved” or “Improved” on the Clinical Global
Impression of Improvement (CGI-I) at Week 12, all the dimen-
sions and the total score were statistically signiﬁcantly improved.
Five of the dimensions, as well as the total score, reached an
effect size of at least 0.50 indicating an at least moderate change
on health status. CONCLUSION: These results strengthen the
usefulness of assessing the impact of schizophrenia on patients’
everyday life with the S-QoL, speciﬁcally designed for assessing
the health-related quality of life of patients with schizophrenia.
Its sensitivity to changes in health state is of major interest for
evaluative purposes.
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OBJECTIVES: The objectives were to develop and validate
a sleep-speciﬁc patient-reported outcomes instrument in
US-English and US-Spanish that can be used in clinical trials.
METHODS: In the development phase, interviews were
conducted with 25 US-English speaking participants suffering
from insomnia. Participants’ comments were reviewed by two
US-Spanish speakers to ensure commonality. Item generation was
conducted simultaneously in the two languages to ensure con-
ceptual equivalence. The face and content validity of the newly
developed instrument (Sleep Impact Scale [SIS]) was tested in 10
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